Grey Matter Neurosciences Secures $14M Seed Funding for Alzheimer's Treatment Technology
- Editor
- Jan 23
- 2 min read
What's Happening: Grey Matter Neurosciences, a Toronto-based neurotechnology company, has licensed advanced focused ultrasound technology from Sunnybrook Research Institute and secured $14 million in seed financing. The funding will support the development of a unique ultrasound headset for potential treatment of Alzheimer's disease.
The Key Moves:
Grey Matter licensed focused ultrasound technology developed at Sunnybrook Research Institute for potential Alzheimer's treatment.
The company raised $14 million in seed financing led by the Wittington Innovation Fund.
Proceeds will fund development of a unique ultrasound headset and clinical trials for Alzheimer's patients.
By The Numbers :
$14 million seed financing secured for technology development and clinical trials.
Focused ultrasound technology can perform non-invasive, precise brain stimulation without external image guidance.
Grey Matter aims to address the $1.6 trillion global cost of dementia care.
Key Quotes:
"Our technology, which can reach the deepest recesses of the brain that control memory and learning, holds massive potential to boost cognition and revolutionize how Alzheimer's and other diseases of the brain are treated." - Dr. Jeffrey Coull, Founder and CEO of Grey Matter
"Sunnybrook Research Institute's latest technology is unparalleled in its combination of accuracy and portability, positioning it to underpin office- and even home-based treatment devices." - Dr. Andy Smith, President and CEO of Sunnybrook Health Sciences Centre
"Grey Matter, whose technology holds so much potential to help people with brain diseases, is an excellent example of the types of ventures we seek to support." - Jim Orlando, Managing Partner of Wittington Ventures
The Bottom Line: Grey Matter Neurosciences is leveraging innovative focused ultrasound technology to potentially transform Alzheimer's treatment. With $14 million in seed funding and support from key investors, the company is poised to develop a novel ultrasound headset that could offer non-invasive, precise brain stimulation for cognitive enhancement in Alzheimer's patients.
Comments